Event Details

Nanobiotix will host a conference call and webcast featuring Nanobiotix chief executive officer and chairman of the executive board, Laurent Levy, on Sunday June 2nd, 2024, at 12:00 PM EDT / 6:00 PM CEST. This event will follow the presentation of updated data from the completed dose escalation part and first data from the ongoing expansion part of Study 1100, a US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) at the 2024 Annual Meeting of the American Society for Clinical Oncology.

Dial-in link: https://register.vevent.com/register/BI6598ae6a87cf4ab9ac097c06a47e0bde